BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15179189)

  • 1. The RAS-BRAF kinase pathway is not involved in uveal melanoma.
    Kiliç E; Brüggenwirth HT; Verbiest MM; Zwarthoff EC; Mooy NM; Luyten GP; de Klein A
    Melanoma Res; 2004 Jun; 14(3):203-5. PubMed ID: 15179189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of BRAF and NRAS mutations in uveal melanoma.
    Cruz F; Rubin BP; Wilson D; Town A; Schroeder A; Haley A; Bainbridge T; Heinrich MC; Corless CL
    Cancer Res; 2003 Sep; 63(18):5761-6. PubMed ID: 14522897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS.
    Zuidervaart W; van Nieuwpoort F; Stark M; Dijkman R; Packer L; Borgstein AM; Pavey S; van der Velden P; Out C; Jager MJ; Hayward NK; Gruis NA
    Br J Cancer; 2005 Jun; 92(11):2032-8. PubMed ID: 15928660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of BRAF mutations in uveal melanoma.
    Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
    Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.
    Deichmann M; Thome M; Benner A; Kirschner M; Hassanzadeh J; Kurzen H
    BMC Cancer; 2005 Jun; 5():58. PubMed ID: 15935100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.
    Edmunds SC; Cree IA; Dí Nícolantonío F; Hungerford JL; Hurren JS; Kelsell DP
    Br J Cancer; 2003 May; 88(9):1403-5. PubMed ID: 12778069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of BRAF mutation in primary uveal melanoma.
    Cohen Y; Goldenberg-Cohen N; Parrella P; Chowers I; Merbs SL; Pe'er J; Sidransky D
    Invest Ophthalmol Vis Sci; 2003 Jul; 44(7):2876-8. PubMed ID: 12824225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.
    Mitsiades N; Chew SA; He B; Riechardt AI; Karadedou T; Kotoula V; Poulaki V
    Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7248-55. PubMed ID: 21828154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.
    Kirschner M; Helmke B; Starz H; Benner A; Thome M; Deichmann M
    Melanoma Res; 2005 Oct; 15(5):427-34. PubMed ID: 16179870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The T1799A point mutation is present in posterior uveal melanoma.
    Janssen CS; Sibbett R; Henriquez FL; McKay IC; Kemp EG; Roberts F
    Br J Cancer; 2008 Nov; 99(10):1673-7. PubMed ID: 18985043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.
    Gorden A; Osman I; Gai W; He D; Huang W; Davidson A; Houghton AN; Busam K; Polsky D
    Cancer Res; 2003 Jul; 63(14):3955-7. PubMed ID: 12873990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF mutations are detectable in conjunctival but not uveal melanomas.
    Spendlove HE; Damato BE; Humphreys J; Barker KT; Hiscott PS; Houlston RS
    Melanoma Res; 2004 Dec; 14(6):449-52. PubMed ID: 15577314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOX10 Expression as Well as BRAF and GNAQ/11 Mutations Distinguish Pigmented Ciliary Epithelium Neoplasms From Uveal Melanomas.
    Mori T; Sukeda A; Sekine S; Shibata S; Ryo E; Okano H; Suzuki S; Hiraoka N
    Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5445-5451. PubMed ID: 29059311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
    Saldanha G; Potter L; Daforno P; Pringle JH
    Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF V600E-dependent role of autophagy in uveal melanoma.
    Zhao Y; Wang W; Min I; Wyrwas B; Moore M; Zarnegar R; Fahey TJ
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):447-455. PubMed ID: 27928645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.
    Maat W; Kilic E; Luyten GP; de Klein A; Jager MJ; Gruis NA; Van der Velden PA
    Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):23-7. PubMed ID: 18172070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NRAS and BRAF mutation frequency in primary oral mucosal melanoma.
    Buery RR; Siar CH; Katase N; Gunduz M; Lefeuvre M; Fujii M; Inoue M; Setsu K; Nagatsuka H
    Oncol Rep; 2011 Oct; 26(4):783-7. PubMed ID: 21750866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line.
    Yu X; Ambrosini G; Roszik J; Eterovic AK; Stempke-Hale K; Seftor EA; Chattopadhyay C; Grimm E; Carvajal RD; Hendrix MJ; Hodi FS; Schwartz GK; Woodman SE
    Pigment Cell Melanoma Res; 2015 May; 28(3):357-9. PubMed ID: 25515650
    [No Abstract]   [Full Text] [Related]  

  • 19. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
    Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
    Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
    Kumar R; Angelini S; Czene K; Sauroja I; Hahka-Kemppinen M; Pyrhönen S; Hemminki K
    Clin Cancer Res; 2003 Aug; 9(9):3362-8. PubMed ID: 12960123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.